China Pharma Holdings (CPHI) Convertible Debt (2021 - 2022)

China Pharma Holdings (CPHI) reported Convertible Debt of $4.8 million for Q2 2022, down 4.04% quarter-over-quarter from $5.0 million in Q1 2022.

China Pharma Holdings (CPHI) Convertible Debt (2021 - 2022) Analysis & Trends

China Pharma Holdings has reported Convertible Debt for 2 years, with the latest figure at $4.8 million in Q2 2022.

For the quarter ending Q2 2022, Convertible Debt changed N/A year-over-year to $4.8 million; the trailing twelve-month figure through Jun 2022 stood at $4.8 million (changed N/A YoY), and the FY2021 full-year result was $5.2 million, changed N/A from the prior year.
Convertible Debt for Q2 2022 stood at $4.8 million, down from $5.0 million in the prior quarter.
The five-year high for Convertible Debt was $5.2 million in Q4 2021, with the low at $4.8 million in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn
10	China Pharma Holdings	18.87 Mn	18.70 Mn	285,487.00

Download Data